A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
一项随机 2a 期研究,旨在探讨使用 tozorakimab 阻断白细胞介素-33 对 COVID-19 住院患者的影响:ACCORD-2
期刊:Erj Open Research
影响因子:4
doi:10.1183/23120541.00249-2023
Wilkinson, Tom; De Soyza, Anthony; Carroll, Miles; Chalmers, James D; Crooks, Michael G; Griffiths, Gareth; Shankar-Hari, Manu; Ho, Ling-Pei; Horsley, Alex; Kell, Chris; Lara, Beatriz; Mishra, Biswa; Moate, Rachel; Page, Clive; Pandya, Hitesh; Raw, Jason; Reid, Fred; Saralaya, Dinesh; Scott, Ian C; Siddiqui, Salman; Ustianowski, Andy; van Zuydam, Natalie; Woodcock, Ashley; Singh, Dave